Literature DB >> 6413106

Comparison between immunopotency tests and specific active or passive acquired resistance against Mycobacterium tuberculosis in mice induced with three different preparations of BCG pasteur vaccine.

M Brandely, B Hurtrel, P H Lagrange.   

Abstract

Tests, exploring hallmarks of cell-mediated immunity (CMI), were used in order to compare immunogenecity of same numbers of viable units from three different preparations of BCG vaccine derived from the same strain. Specific and non-specific cellular immune responses were assessed by several tests including, active and adoptive acquired resistance to Mycobacterium tuberculosis, local and systemic granuloma formation. BCG persistence in the spleen, delayed type hypersensibility (DTH) to tuberculin, immunopotentiation of DTH to sheep red blood cells, increase resistance to Listeria monocytogenes infection and occurrence of non-specific in vitro immunodepression. The ranking order of the three preparations concerning the active specific acquired resistance to tuberculosis did correlate well the ranking established for all immunopotency tests used in our study, however differences in acquired resistance were small as compared to differences observed for immunopotency tests. Moreover, adoptive transfer of same number of lymphoid cells from immune donors gave a different ranking order; the well dispersed fresh frozen (FF) vaccine being more able to induce higher adoptive protection as compared to the mechanically dispersed preparations. All these results clearly demonstrated that BCG could not be considered as single entity and that the test based on acquired resistance to M. tuberculosis or in vivo or in vitro hallmarks of CMI cannot be used as standard procedures.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6413106      PMCID: PMC1536197     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  9 in total

1.  Active suppression of in vitro reactivity of spleen cells after BCG treatment.

Authors:  S Orbach-Arbouys; M F Poupon
Journal:  Immunology       Date:  1978-03       Impact factor: 7.397

2.  Immunological behavior after mycobacterial infection in selected lines of mice with high or low antibody responses.

Authors:  P H Lagrange; B Hurtrel; P M Thickstun
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

3.  Potency of 10 BCG vaccines as evaluated by their influence on the bacillemic phase of experimental airborne tuberculosis in guinea-pigs.

Authors:  D Smith; G Harding; J Chan; M Edwards; J Hank; D Muller; F Sobhi
Journal:  J Biol Stand       Date:  1979-07

4.  Immunopotentiation with BCG. II. Modulation of the response to sheep red blood cells.

Authors:  T E Miller; G B Mackaness; P H Lagrange
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

5.  The host response to Calmette-Guérin bacillus infection in mice.

Authors:  R V Blanden; M J Lefford; G B Mackaness
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

6.  Quantitative comparison of BCG strains and preparations in immunotherapy of a rat sarcoma.

Authors:  N Willmott; M V Pimm; R W Baldwin
Journal:  J Natl Cancer Inst       Date:  1979-09       Impact factor: 13.506

7.  Transfer of adoptive immunity to tuberculosis in mice.

Authors:  M J Lefford
Journal:  Infect Immun       Date:  1975-06       Impact factor: 3.441

8.  [Delayed local reaction (DLR) after BCG vaccination in mice. II.--Correlations with the immune response (author's transl)].

Authors:  P H Lagrange; B Hurtrel
Journal:  Ann Immunol (Paris)       Date:  1978 Apr-Jun

9.  THE IMMUNOLOGICAL BASIS OF ACQUIRED CELLULAR RESISTANCE.

Authors:  G B MACKANESS
Journal:  J Exp Med       Date:  1964-07-01       Impact factor: 14.307

  9 in total
  2 in total

1.  BCG-induced suppressor T cells optimal conditions for in vitro induction and mode of action.

Authors:  A S Mustafa; T Godal
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

2.  Identification of a Mycobacterium bovis BCG auxotrophic mutant that protects guinea pigs against M. bovis and hematogenous spread of Mycobacterium tuberculosis without sensitization to tuberculin.

Authors:  M A Chambers; A Williams; D Gavier-Widén; A Whelan; G Hall; P D Marsh; B R Bloom; W R Jacobs; R G Hewinson
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.